Meeting
2023 ASCO Annual Meeting
Retrospective analysis of genetically matched therapies in salivary gland cancer entities using a real-world database in a tertiary salivary gland cancer expertise center.
Authors
Jetty A.M. Weijers
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands
Jetty A.M. Weijers , Hassan Pazira , Gerald W. Verhaegh , Chantal M.L. Driessen , Adriana CH van Engen - van Grunsven , Marianne A. Jonker , Jack A. Schalken , Carla M.L.- Van Herpen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6098)
DOI
10.1200/JCO.2023.41.16_suppl.6098
Abstract #
6098
Poster Bd #
90
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
PROSPERO: A study to determine the utility of focused genomic profiling to guide selection of drug therapy in salivary gland cancer.
First Author: Samuel Rack
Poster
2023 ASCO Annual Meeting
177Lu-PSMA radioligand therapy for recurrent/metastatic (R/M) salivary gland cancer (SGC) patients: A phase II pilot study.
First Author: Carla M.L.- Van Herpen
Poster
2023 ASCO Annual Meeting
Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy.
First Author: Susumu Okano
Poster
2020 ASCO Virtual Scientific Program
A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.
First Author: Wim van Boxtel